Forte Biosciences, Inc. (FBRX)
FBRX · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2007
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 31, 2026 | Mar 28, 2025 | Mar 18, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 16, 2021 | Feb 27, 2020 | Feb 27, 2019 | Mar 9, 2018 | · |
| Revenue | · | · | · | · | · | · | 36 | 18,036 | 41 | 49 |
| For lenders | ||||||||||
| Net interest income | 2,715 | 1,314 | 1,124 | 162 | · | · | · | · | · | · |
| Research and development | 57,647 | 20,714 | 21,862 | 5,594 | 13,853 | 10,004 | 2,684 | 51,080 | 29,113 | 27,218 |
| General and administrative | 12,410 | 15,409 | 10,624 | 8,302 | 7,633 | 4,221 | 1,380r | 12,809 | 8,556r | 4,521r |
| Total operating expenses | 70,657 | 36,602 | 32,486 | 13,896 | 21,486 | 46,282 | 4,064r | 63,889 | 37,669r | 31,739r |
| Operating income | -70,657 | -36,602 | -32,486 | -13,896 | -21,486 | -46,282 | -4,064r | -45,853 | -37,628r | -31,690r |
| Interest expense | · | · | · | · | · | · | 3,820 | 2,930r | 1,932 | 2,052 |
| Interest and investment income | · | · | · | · | · | · | 1,564 | 1,534 | 595 | 215 |
| Other income (expense), net | -396 | -190 | -114 | -145r | -222 | -205 | -5 | · | · | · |
| Total non-operating income (expense) | 2,319 | 1,124 | · | · | · | · | · | · | -1,300 | -1,787 |
| Income before income taxes | -68,338 | -35,478 | -31,476 | · | · | · | -63,515 | -47,256 | -38,928 | -33,477 |
| Income tax expense | 1,037 | 0 | · | · | · | · | 1 | 1,699 | 1 | 1 |
| Net income including non-controlling interests | -69,375 | -35,478 | · | · | · | · | · | · | · | · |
| Net income | -69,375 | -35,478 | -31,476 | -13,879 | -21,708 | -46,487 | -4,069r | -48,955 | -38,929 | -33,478 |
| Earnings per share, basic | -4.71 | -12.17 | -24.92r | -0.80 | -1.55 | · | · | · | · | · |
| Earnings per share, diluted | -4.71 | -12.17 | -24.92r | -0.80 | -1.55 | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.55 | -6.32 | -1.93r | -2.44 | -2.66 | -15.22 |
| Weighted average shares, basic | · | · | · | 17,383,531 | 13,967,818 | · | · | · | · | · |
| Weighted average shares, diluted | · | · | · | 17,383,531 | 13,967,818 | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 13,967,818 | 7,358,931 | 2,108,266r | 20,059,541 | 14,607,609 | 2,199,964 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebtInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted